<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Background: <z:mpath ids='MPATH_177'>Angiogenesis</z:mpath> is implicated in the pathophysiology and progression of <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Vatalanib (PTK787/ZK222584; Novartis and Schering AG) inhibits receptor tyrosine kinases of vascular endothelial growth factor, platelet derived growth factor and c-Kit </plain></SENT>
<SENT sid="2" pm="."><plain>We examined whether vatalanib induces hematological responses in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and/or delays progression to <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) or <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Methods: Two cohorts were studied </plain></SENT>
<SENT sid="4" pm="."><plain>Vatalanib 1250 mg orally was given once daily (cohort 1) or 750-1250 mg once daily in an intra-patient dose escalating schedule (cohort 2) in 28-day cycles to 155 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>; 142 patients were evaluable for response and 153 for toxicity </plain></SENT>
<SENT sid="5" pm="."><plain>Results: The median age was 70.5 years; 51 % had low risk (International Prognostic Scoring System {IPSS} Low/Intermediate-1) and 32 % had high risk (IPSS Intermediate-2/High) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Hematological improvement was achieved in 7/142 (5 %) patients; <z:hpo ids='HP_0000001'>all</z:hpo> 7 were among the 47 patients able to remain on vatalanib for at least 3 months (hematological improvement achieved in 15 % of these 47 patients) </plain></SENT>
<SENT sid="7" pm="."><plain>For patients with low risk and high risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, respectively, median progression-free survivals were 15 and 6 months, median times to transformation to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> were 28 and 6 months, and median overall survivals were 36 and 10 months </plain></SENT>
<SENT sid="8" pm="."><plain>The most frequent non-hematological adverse events grade ≥2 were <z:mp ids='MP_0002899'>fatigue</z:mp>, <z:hpo ids='HP_0002018'>nausea</z:hpo> or <z:hpo ids='HP_0002013'>vomiting</z:hpo>, dizziness, <z:hpo ids='HP_0002039'>anorexia</z:hpo>, <z:hpo ids='HP_0001251'>ataxia</z:hpo>, <z:hpo ids='HP_0002014'>diarrhea</z:hpo>, and pain </plain></SENT>
<SENT sid="9" pm="."><plain>Two <z:hpo ids='HP_0011420'>deaths</z:hpo> (one intra-<z:hpo ids='HP_0001342'>cerebral hemorrhage</z:hpo> and one <z:hpo ids='HP_0001699'>sudden death</z:hpo>) were possibly related to vatalanib </plain></SENT>
<SENT sid="10" pm="."><plain>Conclusions: Vatalanib induces improvement in blood counts in a small proportion of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
<SENT sid="11" pm="."><plain>Clinical applicability is limited by side effects </plain></SENT>
</text></document>